Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company will present and participate in the Sachs Associates 9th Annual Neuroscience Innovation Forum on January 11, 2026 during “J.P. Morgan Week 2026” in San Francisco. Additionally, Enveric will attend Biotech Showcase 2026, which is being held from January 12-14, 2026.

During the events, members of Enveric’s management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.

Details are as follows:

Event:	Sachs Associates 9th Annual Neuroscience Innovation Forum
Panel:	Meeting the Promise of Psychedelics Panel: Expected Trends for 2026
Location:	Marines’ Memorial Club
Registration:	https://www.sachsforum.com/9nif-registration.html

Event:	Biotech Showcase 2026
Date & Time	January 12–14, 2026
Location:	Hilton San Francisco Union Square
Registration:	https://informaconnect.com/biotech-showcase/registration-options/

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT₂_A and 5-HT₁_B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.